Select Page
ONEpossible 2022

ONEpossible 2022

In 2020, PRF checked off an important mission milestone: U.S. Food and Drug Administration (FDA) approval of lonafarnib (brand name Zokinvy®), the first-ever treatment for Progeria. Since then, and through tremendous effort and expense, PRF and partner Eiger...
Get PRF’s 2021 Annual Newsletter here!

Get PRF’s 2021 Annual Newsletter here!

Check out our newsletter to read about FDA approval for the first-ever treatment for Progeria, learn how the research we fund has made remarkable progress toward the cure through genetic and RNA therapies, and get the scoop on all the exciting milestones we’re...